Page 3 - ஜூ இ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஜூ இ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஜூ இ Today - Breaking & Trending Today
Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Interim Results and Business Updates investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
微纪录片+短视频+直播,总台央视纪录频道联合快手开启中国世界遗产地神奇之旅 sootoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sootoo.com Daily Mail and Mail on Sunday newspapers.
Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Stabilizing Actions & End of Stabilization Period investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Hutchison China MediTech Limited (AIM:HCM) | RNS | Hutchmed China Ltd proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Share: – EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval – HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ( EMA ) has validated and accepted its marketing authorization application ( MAA ) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors ( NETs ). The EMA s validation confirms that the submission is sufficiently complete and that it is ready to commence the formal review process. ....